EUVIMEDEUVIMED entdecken
Leserbrief

Survival Analysis in a Colombian Cohort of Mantle Cell Lymphoma. A Real‐World Experience

Juan F Combariza-Vallejo iD, Rocío Orduz-Rodriguez iD, Natalia Gomez-Lopera iD, Claudia C Colmenares-Mejia iD, Fabián A Mejía-Casadiego, Marcela Godoy-Corredor iD, Mario Arturo Isaza-Ruget iD

Hematological Oncology · 2025

DOI: 10.1002/hon.70085 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Hematological Oncology, 2025. Verfasst von Juan F Combariza-Vallejo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Service, Clinica Universitaria Colombia, Clinica Colsanitas, Grupo Keralty, Bogotá, Colombia. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle cell lymphoma is a type of B‐cell lymphoma with limited epidemiologic data in Latin America. The main objective was evaluating survival, in mantle cell lymphoma in Colombia and the influence of hematopoietic stem cell transplantation in the outcomes. In a retrospective cohort of new diagnostic Mantle Cell Lymphoma between 2010 and 2024, we identified main characteristics at diagnosis and the influence of MIPI score and ASCT. We followed patients until progression or death and compared progression‐free survival and overall survival. We included 139 patients; the median age was 64 years. For patients classified as low risk according to the MIPI score, the 36‐month OS rate was 79.7% (95% CI: 68%–93.5%). Intermediate risk 51.5% (95% CI: 38.2%–69.4%). And High‐risk 40.4% (95% CI: 26.9%–59.5%) ( p < 0.001). In the group that underwent ASCT, the 36‐month OS rate was 75.2% (95% CI: 60.1%–94.6%), and in the non‐transplanted group was 49% (95% CI: 39.5%–60.7%), HR 0.38 (95% CI; 019–0.74) ( p = 0.002). High‐risk patients and those who were not transplanted had the lowest survival compared to the other categories. These findings underscore the need for risk stratification, and effective treatment strategies, including the HSCT patient population in Colombia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellHematopoietic Stem Cell TransplantationHumansMaleFemaleMiddle AgedColombiaAgedRetrospective StudiesAdultSurvival RatePrognosisSurvival AnalysisFollow-Up StudiesAged, 80 and over

Stichwörter der Autor:innen

hematopoietic stem cell transplantationmantle cell lymphomasurvival analysis

Autor:innen und Institutionen

  • Hematology Service, Clinica Universitaria Colombia, Clinica Colsanitas, Grupo Keralty, Bogotá, Colombia.
  • Clinical and Pathology Laboratory, Clinica Colsanitas, Grupo Keralty, Bogotá, Colombia.
  • Research Unit, Fundación Universitaria Sanitas, Grupo de Investigación INPAC, Bogotá, Colombia.

ORCID-Profile: Juan F Combariza-Vallejo, Rocío Orduz-Rodriguez, Natalia Gomez-Lopera, Claudia C Colmenares-Mejia, Marcela Godoy-Corredor, Mario Arturo Isaza-Ruget

Zitieren

APA

Combariza-Vallejo, J. F., Orduz-Rodriguez, R., Gomez-Lopera, N., Colmenares-Mejia, C. C., Mejía-Casadiego, F. A., Godoy-Corredor, M., & Isaza-Ruget, M. A. (2025). Survival Analysis in a Colombian Cohort of Mantle Cell Lymphoma. A Real‐World Experience. Hematological Oncology. https://doi.org/10.1002/hon.70085

Vancouver

Combariza-Vallejo JF, Orduz-Rodriguez R, Gomez-Lopera N, Colmenares-Mejia CC, Mejía-Casadiego FA, Godoy-Corredor M, et al. Survival Analysis in a Colombian Cohort of Mantle Cell Lymphoma. A Real‐World Experience. Hematological Oncology. 2025. doi:10.1002/hon.70085

BibTeX
@article{CombarizaVallejo2025,
  author = {Combariza-Vallejo, Juan F and Orduz-Rodriguez, Rocío and Gomez-Lopera, Natalia and Colmenares-Mejia, Claudia C and Mejía-Casadiego, Fabián A and Godoy-Corredor, Marcela and Isaza-Ruget, Mario Arturo},
  title = {Survival Analysis in a Colombian Cohort of Mantle Cell Lymphoma. A Real‐World Experience},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70085}
}
Kostenlos starten →